EDAP TMS S.A., each representing One Ordinary Share (EDAP) Company Bio
EDAP TMS S.A. develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases worldwide. The company was founded in 1979 and is based in Vaulx-en-Velin, France.
EDAP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Edap Tms Sa. To summarize, we found that Edap Tms Sa ranked in the 32th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Edap Tms Sa ended up being:
As a business, EDAP is generating more cash flow than merely 8.09% of positive cash flow stocks in the Healthcare.
The business' balance sheet reveals debt to be 6% of the company's capital (with equity being the remaining amount). Approximately merely 16.85% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
EDAP's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 42.39% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as EDAP, try OSMT, GILD, IQV, MD, and QDEL.
EDAP (EDAP) is surviving the drought of hospitals buying new stuff as a result of the pandemic being quite a bit better than many would have thought, which is why their share price has recovered nicely after encouraging Q2 results: We wrote in October last year that the company was...
Shareholders Unite on Seeking Alpha | September 16, 2020
Thinly traded nano cap EDAP TMS SA ([[EDAP]] +30.9%) is up a 9x surge in volume on the heels of its update on recent sales of its Focal One HIFU device.In Q2, Lyon, France-based Edouard Herriot University Hospital and Ochsner Medical Center in New Orleans, LA signed on. Both sales...